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HTN, obesity, dyslipidemia are often various symptoms 
of a metabolic disorder called Metabolic Syndrome 
(MS).Various bodies have defined metabolic syndrome 
based on biochemical parameters and clinical 
examination. According to National Cholesterol 
Education Programme – Adult Treatment Plan III 
(NCEP ATP III)1, presence of any three of the 
followings make the diagnosis of metabolic syndrome. 
Abdominal obesity (Waist circumference) 
Men >102 cm (>40 inch)  
Women >88 cm (>35 inch) 
Triglycerides >150 mg/dL 
HDL cholesterol 
Men < 40 mg/dL 
Women < 50 mg/dL 
Blood pressure >130/>85 mmHg 
Fasting glucose >110 mg/dL 
International Diabetes Federation (IDF) has defined 
metabolic syndrome by presence of: 
Central obesity (defined as waist circumference ≥ 90cm 
for South Asian men and ≥ 80cm for South Asian 
women, with ethnicity specific values for other groups) 
Plus any two of the following four factors: 
• Raised TG level: ≥ 150 mg/dL (1.7 mmol/L), or 
specific treatment for this lipid abnormality 
•Reduced HDL cholesterol: < 40 mg/dL (1.03 mmol/L) 
in males and < 50 mg/dL (1.29 mmol/L) in females, or 
specific treatment for this lipid abnormality 
• Raised blood pressure: systolic BP ≥ 130 or diastolic 
BP ≥ 85 mm Hg, or treatment of previously diagnosed 
hypertension 
• Raised fasting plasma glucose (FPG) ≥ 100 mg/dL 
(5.6 mmol/L), or previously diagnosed type 2 diabetes 
As per the IDF Consensus Worldwide Definition of the 
Metabolic Syndrome, both IR and central obesity are 
considered the principal factors responsible for clustering 
of the pentad of CVD risk factors in MS. As per NCEP-
ATP III, overweight and obesity are associated with 
insulin resistance and the metabolic syndrome. However, 
the presence of abdominal obesity is more highly 
correlated with the metabolic risk factors than is an 
elevated body mass index (BMI). 
An estimated 47 million U.S. residents have the 
metabolic syndrome2. Epidemiological studies have 
recorded a high prevalence of metabolic syndrome3, 4, 5 
and cardiovascular mortality6, 7, 8 among Indians, 
including those settled outside of India. 
Gamma Glutamyl Transferase (GGT) is an enzyme 
which is used as a marker of alcohol intake and 
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subsequent hepatic injury. Cellular GGT is widely 
distributed in human body and is usually localized to the 
plasma membrane with its active site directed into the 
extracellular space9. The highest activity of GGT is 
found in kidney, on the luminal surface of proximal 
tubular cells. Interestingly, although serum GGT is 
known as one of the liver enzymes, cellular GGT activity 
in homogenates of liver is approximately one-fifth that in 
kidney. Principal role of GGT is to breakdown 
extracellular reduced GSH, allowing the precursor amino 
acids to be assimilated into cell and reutilized for 
intracellular GSH synthesis. 
Essential hypertension is often associated with insulin 
resistance (IR). 25-50 % of non-obese, non-diabetic 
patients with EHTN have IR1. 
In some studies, a significant association was found 
between serum GGT level and prehypertension10 (SBP 
130-139 and/or DBP 80-89) and hypertension11. 
Furthermore, GGT level has been found to be good 
predictor of susceptibility to type II diabetes mellitus12,13 
and hypertension8. Considering these atypical features of 
GGT and keeping in mind that the above-mentioned 
studies have been carried out in people of different 
ethnicity, there is a perceived need to verify if the 
association between GGT and MS holds for eastern 
Indian population too. 
MATERIALS AND METHODS 
The study samples were collected from the OPD of 
Clinical Biochemistry Laboratory at the Department of 
Biochemistry, Medical College, Kolkata. The study 
subjects included both male and female MS patients and 
age and sex matched non MS individuals in the age 
group of 18-35 years. 
The study period spanned from December 2011 to March 
2012.  
Total 185 patients were enrolled into the study. Of them, 
91 had MS and 94 were controlled individuals. The 
applied selection criteria were as follows: 
Inclusion Criteria 
Patients of either sex aged 18 to 35 years and diagnosed 
with metabolic syndrome on the basis of NCEP ATP III 
criteria with age and sex matched controls, who attended 
the OPDs during the study period and gave their 
voluntary written informed consent for the study. 
Exclusion Criteria 
 Pregnant and lactating mothers. 
 If the patient is suffering from any of the following 
conditions: 
1. Renal Disease 
2. Liver Disease 
3. Cardiac Disease 
4. Active Infection 
5. Any malignancy 
6. Known alcoholic patients. 
Study Protocol: Sample Collection, Analysis 
Before collection of data or blood sample, each patient 
was explained the details of the study including rationale, 
expected benefits, risk profile, confidentiality safeguards 
and study protocol. For some patients, help of 
appropriate interpreter(s) was taken. Only those patients 
who were willing to follow the study protocol and gave 
their written consent were included in the study. There 
was neither any financial cost nor any financial incentive 
for the patient for being part of the study. 
1. Appropriate blood samples were collected from MS 
patients and age and sex matched non MS 
individuals. For estimation of serum GGT, 
cholesterol, triglyceride, HDL and plasma glucose 
fasting blood sample were drawn into serum 
(without anticoagulant) gel containing yellow colour 
capped BD Vacutainer tubes. All samples were 
immediately centrifuged and stored at 2-8oC until 
analysis for the relevant biochemical parameters. All 
analyses were performed within 3 hours of sample 
collection. 
2. Serum Cholesterol was measured by XL600 
autoanalyzer using CHOD-PAP principle. 
3. Serum Triglyceride was measured by XL600 
autoanalyzer using Glycerol Kinase principle. 
4. Serum HDL was measured by ERBA Chem 5 V2 
semi-autoanalyzer using PEG Precipitation 
principle. 
5. Serum GGT level was measured by XL600 
autoanalyzer using Gamma Glutamyl p-
Nitroanilidine (GPNA) principle. 
6. Plasma glucose was measured by XL600 
autoanalyzer using GOD-POD principle. 
7. Serum Albumin was measured by XL600 
autoanalyzer using BCG principle. 
8. Serum total protein was measured by XL600 
autoanalyzer using Biuret principle. 
9. Patients’ recent-most blood/plasma/serum values of 
the afore-mentioned biochemical parameters were 
noted, if already available, provided they were done 
on the same day. 
Patients’ relevant anthropometric data were collected. 
The serum levels of GGT, Cholesterol, Triglyceride, 
HDL and fasting plasma glucose levels of the two groups 
were compared for presence or absence of statistically 
significant differences. 
Statistical Analysis 
The statistical software R version 2.11.1 was used to 
analyze the data. All values were expressed as mean + 
standard deviation unless otherwise indicated, and 
differences in mean values between two groups were 
analysed using Student’s t-test (Table 1). Descriptive 
information regarding categorical variable were 
presented as frequency. Fischer’s exact probability test 
was used for comparison of categorical data. All tests 
were two tailed and considered statistically significant if 
p-value < level of significance, 0.05. 
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RESULTS 
The present study confirms the finding of earlier studies 
that serum GGT level in MS patients is higher than their 
non MS counterparts (p=0.007). There were no 
significant differences in age, serum albumin, serum total 
protein between the two groups. Serum levels of 
cholesterol, triglyceride, HDL and fasting plasma 
glucose levels were significantly different in two groups. 
Systolic blood pressure was also found to be higher 
among the MS group, which stood statistically 
significant.
 
Table 1: The biochemical parameters of MS and non MS groups 
 Control Group MS Group p-value 
Number of patients 94 91  
Male/Female 56/38 50/41 0.62 
Age (years) 27.02 + 6.78 26.81 + 7.81 0.177 
SBP (mmHg) 126+12 130 + 16 0.006* 
DBP (mmHg) 79 + 9 81 + 8 0.262 
Waist Circumference (cm) 79 + 8 89 + 10 0.033* 
Total Protein (g/dL) 7.1 + 0.5 6.9 + 0.6 0.082 
Albumin (g/dL) 5.1 + 0.6 4.9 + 0.5 0.083 
Cholesterol (mg/dL) 177 + 56 211 + 62 0.331 
Triglyceride (mg/dL) 129 + 39 169 + 48 0.048* 
Fasting Plasma Glucose (mg/dL) 86 + 12 92 + 15 0.033* 
HDL (mg/dL) 46 + 8 39 + 6 0.006* 
Gamma glutamyltransferase (U/L) 43.7 + 51.7 61.8 + 68.2 0.007* 
* p<0.05 is considered to be statistically significant 
DISCUSSION 
Our study confirms the empirical validity of the 
observation made in earlier studies that serum GGT level 
is higher in metabolic syndrome patients compared to 
age and sex matched normal individuals.  
GGT has hitherto been used as a marker of alcohol 
consumption14. In earlier studies, it had been shown that 
correlation between GGT and hypertension is 
independent of alcohol intake15. A similar significant 
association had been found among non-drinkers16 too. 
However, another study, taking the contribution of 
insulin level in determining GGT level, had established a 
non-significant correlation between GGT level and 
hypertension but a significant correlation between GGT 
level and plasma insulin level17. Further credence has 
been lent to the hypothesis that plasma insulin level is 
the principal determinant of GGT in metabolic syndrome 
patients and hypertensives18. 
A mechanism has been put forward to account for the 
pathological role of insulin in elevation of GGT. 
Elevated insulin level may lead to hepatic steatosis19,20,21, 
and subsequently, Non Alcoholic Fatty Liver Disease 
(NAFLD). Steatosis appears when insulin secretion is 
sufficient to block free fatty acid oxidation but not 
sufficient to block free fatty acid mobilization from 
adipose tissue22. Free fatty acids are markedly cytotoxic 
and may cause alteration in hepatic cell membrane 
function and leakage of GGT23.  
GGT is also known to act as an antioxidant by virtue of 
its central role in GSH cycle. Hypertension being a state 
of high oxidative stress, elevated GGT level can be 
explained as a compensatory mechanism24. 
Furthermore, recent studies have revealed a pro-oxidant 
generating25,26,27,28 role of GGT. GGT generates ROS in 
presence of free iron or other transition metal. These 
authors suggested that the GGT mediated generation of 
the more reactive thiol cysteinyl‐ glycine could cause the 
reduction of ferric iron Fe(III) to ferrous Fe(II), thus 
starting a redox‐ cycling process liable to result in the 
production of reactive oxygen species (ROS). 
Considering that insulin stimulates ferritin 
synthesis29,30,31 and hypertension is a hyperinsulinemic 
state, it is more likely than not that hypertensive 
individuals have higher ferritin level. In vitro 
experimental studies have reported that free iron can be 
released from iron storage proteins such as ferritin by 
superoxide radicals or nitric oxide32,33,34. It is well known 
that substantial oxidative stress exists in diabetes35,36 and 
hypertension37,38. Therefore, patients with diabetes or 
hypertension might have a potential to have free iron 
released from iron storage protein, and in this case, 
cellular GGT might act as a pro-oxidant. 
CONCLUSION 
The results of this population-based cross-sectional study 
suggest that GGT may serve as a marker for metabolic 
syndrome. It should be borne in mind in the clinical 
practice that elevated levels of GGT may not always 
indicate increased alcohol consumption, but may simply 
suggest the existence of metabolic syndrome with its 
subsequent deleterious consequences viz. type II diabetes 
mellitus, hypertension and carotid atherosclerosis. 
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